JAK1 and COVID-19: Initial case series and explorative studies found that patients with severe COVID-19 who were treated with eculizumab, including in combination with the JAK1/2 inhibitor ruxolitinib (Diurno et al., 2020; Giudice et al., 2020; Laurence et al., 2020; Mastellos et al., 2020), experienced more positive clinical outcomes.